Journey Medical Corp
DERM8.010USD
+0.140+1.78%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
211.24MMarket Cap
LossP/E TTM
More Details of Journey Medical Corp Company
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Journey Medical Corp Info
Ticker SymbolDERM
Company nameJourney Medical Corp
IPO dateNov 12, 2021
CEOMaraoui (Claude)
Number of employees41
Security typeOrdinary Share
Fiscal year-endNov 12
Address9237 E Via De Ventura Blvd., Suite 105
CitySCOTTSDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code85258
Phone14804346670
Websitehttps://journeymedicalcorp.com/
Ticker SymbolDERM
IPO dateNov 12, 2021
CEOMaraoui (Claude)
Company Executives of Journey Medical Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+53.80%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%
By RegionUSD
Name
Revenue
Proportion
United States
15.01M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
15.90%
Maraoui (Claude)
9.75%
Tang Capital Management, LLC
8.77%
Wasatch Global Investors Inc
6.18%
Opaleye Management Inc.
4.59%
Other
54.80%
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
15.90%
Maraoui (Claude)
9.75%
Tang Capital Management, LLC
8.77%
Wasatch Global Investors Inc
6.18%
Opaleye Management Inc.
4.59%
Other
54.80%
Shareholder Types
Shareholders
Proportion
Corporation
15.90%
Individual Investor
15.49%
Hedge Fund
14.72%
Investment Advisor
12.26%
Investment Advisor/Hedge Fund
11.73%
Private Equity
1.08%
Insurance Company
0.85%
Research Firm
0.40%
Pension Fund
0.20%
Other
27.36%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
2023Q3
44
2.15M
17.23%
+484.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
3.36M
16.55%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
10.15%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
9.13%
--
--
Jun 30, 2025
Wasatch Global Investors Inc
1.15M
5.67%
+221.46K
+23.80%
Jun 30, 2025
The Vanguard Group, Inc.
564.99K
2.78%
+192.73K
+51.77%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
480.30K
2.36%
+437.14K
+1012.83%
Jun 30, 2025
Rosenwald (Lindsay A)
377.89K
1.86%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
228.20K
1.12%
+216.74K
+1890.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Journey Medical Corp?
The top five shareholders of Journey Medical Corp are:
Fortress Biotech Inc holds 3.36M shares, accounting for 16.55% of the total shares.
Maraoui (Claude) holds 2.06M shares, accounting for 10.15% of the total shares.
Tang Capital Management, LLC holds 1.85M shares, accounting for 9.13% of the total shares.
Wasatch Global Investors Inc holds 1.15M shares, accounting for 5.67% of the total shares.
The Vanguard Group, Inc. holds 564.99K shares, accounting for 2.78% of the total shares.
Fortress Biotech Inc holds 3.36M shares, accounting for 16.55% of the total shares.
Maraoui (Claude) holds 2.06M shares, accounting for 10.15% of the total shares.
Tang Capital Management, LLC holds 1.85M shares, accounting for 9.13% of the total shares.
Wasatch Global Investors Inc holds 1.15M shares, accounting for 5.67% of the total shares.
The Vanguard Group, Inc. holds 564.99K shares, accounting for 2.78% of the total shares.
What are the top three shareholder types of Journey Medical Corp?
The top three shareholder types of Journey Medical Corp are:
Fortress Biotech Inc
Maraoui (Claude)
Tang Capital Management, LLC
Fortress Biotech Inc
Maraoui (Claude)
Tang Capital Management, LLC
How many institutions hold shares of Journey Medical Corp (DERM)?
As of 2025Q4, 111 institutions hold shares of Journey Medical Corp, with a combined market value of approximately 6.92M, accounting for 29.29% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.83%.
What is the biggest source of revenue for Journey Medical Corp?
In FY2025Q2, the Qbrexa business generated the highest revenue for Journey Medical Corp, amounting to 6.95M and accounting for 46.30% of total revenue.
